BIOVAXYS
BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is... a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
BIOVAXYS
Industry:
Biopharma Biotechnology
Founded:
2018-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.biovaxys.com
Total Employee:
1+
Status:
Active
Contact:
610 977 2440
Total Funding:
4.94 M USD
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2022-09-08 | BioVaxys Announces New Chief Financial Officer |
Official Site Inspections
http://www.biovaxys.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "BioVaxys"
BioVaxys - Crunchbase Company Profile & Funding
BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The …See details»
BioVaxys Technology Corp. - LinkedIn
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF, FR:5LB), formerly BioVaxys LLC, is a British Columbia-registered clinical-stage biotechnology company dedicated to improving …See details»
BioVaxys Technology Corp. (BIOV.CN) - Yahoo Finance Canada
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune …See details»
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL …
Feb 21, 2024 At the closing, BioVaxys delivered to HIMV a one-time payment of both US$750,000 in cash and 5,034,701 common shares of BioVaxys at a deemed price of …See details»
BioVaxys Acquires All Intellectual Property, Immunotherapeutics ...
Feb 12, 2024 The deal also assigns to Biovaxys a royalty-bearing License and Supply Agreement with Wisconsin-based SpayVac for Wildlife Inc., on sales of animal vaccine …See details»
Biovaxys Technology Corp, BVAXF:QBB profile - FT.com
BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX …See details»
Biovaxys Technology Corp (BIOV-CN) Stock Price and News
Real-time Price Updates for Biovaxys Technology Corp (BIOV-CN), along with buy or sell indicators, analysis, charts, historical performance, news and moreSee details»
BioVaxys in Non-Binding Discussions for Major ... - Nasdaq
--BioVaxys Technology Corp. announced today that it is in non-binding discussions to acquire an immunotherapeutics intellectual property portfolio of discovery, preclinical and clinical ...See details»
BVAXF Stock Price Quote | Morningstar
6 days ago BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating …See details»
BioVaxys to Participate in the US Government Biomedical …
VANCOUVER, BC, Nov. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it …See details»
BioVaxys Initiates Cancer Vaccine EU Clinical Program, Completes …
Jan 28, 2021 BioVaxys is in discussions with its designated Contract Manufacturing Organization (CMO) and anticipates the execution of a manufacturing contract in 1Q21. The …See details»
BioVaxys Acquires All Intellectual Property ... - Nasdaq
Feb 12, 2024 The deal also assigns to Biovaxys a royalty-bearing License and Supply Agreement with Wisconsin-based SpayVac for Wildlife Inc., on sales of animal vaccine …See details»
BioVaxys SARS-CoV-2 Vaccine Candidate BVX-0320 Stimulates
Feb 2, 2021 About BioVaxys Technology Corp. Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing …See details»
BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP
Nov 20, 2024 Kenneth Kovan, BioVaxys President & Chief Operating Officer, stated, "SpayVac for Wildlife, already a leader in developing breeding control, will leverage its scaled-up …See details»
BioVaxys Announces Bioproduction of BVX-1021 for its Pan …
Mar 17, 2022 BioVaxys intends to develop BVX-1021 as a standalone "booster" targeting anyone who has been immunized with a World Health Organization-recognized Covid-19 …See details»
BioVaxys' DPX Exhibits Superior Immune System Activation
Oct 31, 2024 "BioVaxys is at the forefront of a significant shift in the drug delivery landscape," James Passin, CEO of BioVaxys, stated, "These groundbreaking study results validate our …See details»
BioVaxys Confirms First Clinical Site and Principal ... - Nasdaq
--BioVaxys Technology Corp., announced today that Hospices Civils de Lyon, France has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous ...See details»
BioVaxys Technology Corp. (BVAXF) Stock Price, Quote, News
Nov 25, 2024 A high-level overview of BioVaxys Technology Corp. (BVAXF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.See details»
BioVaxys Enters Critical Tumor Cell Supply Agreement with …
Apr 25, 2022 BioVaxys President & Chief Operating Officer Kenneth Kovan says, "Having complied with the regulatory oversight involved in obtaining waste tumor samples, BioVaxys is …See details»